Cortexyme Inc represents values and a corporate philosophy focused on innovative research and development in the field of neurodegenerative diseases. The company aims to advance scientific knowledge and discoveries to develop transformative therapies for conditions like Alzheimer's and Parkinson's disease. Cortexyme Inc is committed to improving the lives of patients and approaching neurological disorders with a holistic understanding of the underlying mechanisms. With their dedication to scientific rigor, patient-centered approach, and commitment to delivering novel treatments, Cortexyme Inc is at the forefront of combating neurodegenerative diseases and creating a better future for patients worldwide.

Cortexyme Inc is primarily present in the United States.

Cortexyme Inc has achieved several significant milestones. The company successfully completed Phase 1 clinical trials for its lead drug candidate, COR388, which showed promising results in targeting a key protein related to Alzheimer's disease. Cortexyme also received Fast Track designation from the U.S. FDA for the development of COR388 in treating Alzheimer's disease. Furthermore, the company raised substantial funding through its initial public offering (IPO) and subsequent stock offerings, enabling them to advance their pipeline of potential therapies. Cortexyme's milestones highlight their dedication to developing innovative treatments for neurodegenerative diseases like Alzheimer's, positioning them as a key player in the healthcare industry.

Cortexyme Inc. is a biopharmaceutical company that focuses on developing therapeutics for neurodegenerative diseases. Founded in 2012, Cortexyme is headquartered in South San Francisco, California. The company's mission is to discover and develop disease-modifying therapies to improve the lives of patients with Alzheimer's disease and other aging-related disorders. Cortexyme's innovative approach involves targeting specific pathogenic bacteria that have been found in the brain, aiming to inhibit the production of toxic molecules that contribute to disease progression. With a dedicated team of researchers and partnerships with leading academic institutions, Cortexyme is at the forefront of pioneering treatments for neurodegenerative diseases.

The main competitors of Cortexyme Inc in the market include pharmaceutical companies focused on developing treatments for neurodegenerative diseases, such as Biogen Inc, Eli Lilly and Company, and AbbVie Inc. These industry leaders compete with Cortexyme in the development of novel therapies targeting conditions like Alzheimer's disease. Additionally, smaller biotech companies specializing in neurology research and drug discovery may also pose competition to Cortexyme Inc.

Cortexyme Inc is primarily active in the biotechnology industry.

Cortexyme Inc's business model focuses on the development of therapeutics focusing on the treatment of Alzheimer's disease and other degenerative disorders. The company aims to identify and target specific pathogens that are believed to play a role in the development and progression of these diseases. By exploring the connection between bacterial infections and neurodegenerative conditions, Cortexyme Inc aims to develop innovative drugs to target these underlying causes. Their pharmaceutical research and development team utilize a proprietary drug discovery platform to identify potential drug candidates. Cortexyme Inc aims to bring novel therapies to market that can potentially improve the lives of patients suffering from Alzheimer's disease and related disorders.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Quince Therapeutics.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Quince Therapeutics.

Το AlleAktien Qualitätsscore για το Quince Therapeutics είναι 1/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Quince Therapeutics.

Τα κέρδη για τον Quince Therapeutics δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Cortexyme Inc is a biotechnology company driven by the discovery of new therapies for neurodegenerative diseases such as Alzheimer's through the use of advanced technologies and innovative research approaches. The company's goal is to identify the underlying causes of neurodegenerative diseases and develop new therapies that target the disease's causes rather than just treating the symptoms. The business model of Cortexyme Inc is based on the research and development of drugs for neurodegenerative diseases. The company has three main divisions: Science and Development, Finance and Marketing, and Regulation and Quality Assurance. In the Science and Development division, the company works to gain new insights into the fundamentals of neurodegenerative diseases and develop innovative therapies based on these insights. The focus is on principles of molecular research, medical technology, and drug development. Cortexyme Inc collaborates closely with leading research institutions worldwide to advance research and develop new technologies to identify the causes of neurodegeneration. The company also utilizes big data analysis and artificial intelligence to generate new insights and accelerate research. One of Cortexyme's key therapeutic areas is the drug CX-525, which targets specific bacterial pathogens with an antibiotic effect that are linked to neurodegenerative diseases (such as Alzheimer's). The drug aims to treat the underlying causes of the disease and thus combat the symptoms. CX-525 was approved by the US Food and Drug Administration (FDA) for clinical trials in 2018. Also in development are the drugs CX-2009 & CX-2029, which target the protein aggregates in the brains of Alzheimer's patients. Cortexyme Inc is also known for its strong support for the patient community. The company works closely with charitable organizations to raise awareness of neurodegenerative diseases and increase understanding of the disease. Through this collaboration, resources can be provided to develop new therapies and help patients and their families make informed treatment choices. Overall, Cortexyme Inc has successfully pursued its goal of developing new research findings and effective therapies against neurodegenerative diseases. The company relies on a combination of innovation, partnership, and industry experience to create better treatment options for patients suffering from these diseases. As a pioneer in the industry, Cortexyme Inc has the potential to make significant advancements towards better healthcare worldwide.

Η Quince Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Quince Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Quince Therapeutics είναι US22053A1079.

Το WKN της Quince Therapeutics είναι A2PHHD.

Ο τίκερ της Quince Therapeutics είναι QNCX.

Κατά τους τελευταίους 12 μήνες η Quince Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Quince Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Quince Therapeutics ανέρχεται σήμερα στο .

Quince Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Quince Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Quince Therapeutics ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Quince Therapeutics από την 1/8/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 1/8/2024.

Η τελευταία μερίσματος έγινε στις 1/8/2024.

Το έτος 2023, η Quince Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Quince Therapeutics καταβάλλονται σε USD.